Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Payables (2022 - 2025)

Axsome Therapeutics' Payables history spans 4 years, with the latest figure at $65.5 million for Q4 2025.

  • For Q4 2025, Payables fell 8.97% year-over-year to $65.5 million; the TTM value through Dec 2025 reached $65.5 million, down 8.97%, while the annual FY2025 figure was $65.5 million, 8.97% down from the prior year.
  • Payables for Q4 2025 was $65.5 million at Axsome Therapeutics, up from $54.2 million in the prior quarter.
  • Across five years, Payables topped out at $170.9 million in Q2 2025 and bottomed at $11.0 million in Q1 2022.
  • The 4-year median for Payables is $56.5 million (2023), against an average of $70.0 million.
  • The largest annual shift saw Payables soared 510.79% in 2023 before it crashed 55.62% in 2025.
  • A 4-year view of Payables shows it stood at $51.6 million in 2022, then fell by 21.21% to $40.7 million in 2023, then soared by 76.99% to $72.0 million in 2024, then decreased by 8.97% to $65.5 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Payables are $65.5 million (Q4 2025), $54.2 million (Q3 2025), and $170.9 million (Q2 2025).